{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-26-000046","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2026-07-08T20:13:40+00:00","discovered_at":"2026-07-08T20:14:00.650971+00:00","generated_at":"2026-07-08T20:14:04.410884+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tarsus acquires iRenix Medical for ~$75M upfront; adds late-stage ocular antiseptic IRX-101","bullets":["Upfront consideration of $75M: $37.5M cash + $37.5M in Tarsus common stock (607,093 shares).","Potential approval/commercial milestones up to $490M plus low-to-mid single-digit revenue sharing.","IRX-101 Phase 2b/3 RELIEF trial: ~50% relative reduction in post-procedural pain (p=0.0003) vs povidone-iodine.","Phase 3 study expected to start H1 2027 with results in 2028; FDA-aligned program.","Over 11M intravitreal injections performed annually in US; no new FDA-approved ocular antiseptic in >40 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-26-000046","json":"https://secwatch.observer/filing/0001819790-26-000046.json","markdown":"https://secwatch.observer/filing/0001819790-26-000046.md","text":"https://secwatch.observer/filing/0001819790-26-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000046/0001819790-26-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000046/tars-20260706.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-08T20:14:04.410884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}